From Epidemiology and Genetics to Diagnostics, Outcome Measures, and Novel Treatments in Autoimmune Bullous Diseases

Ludwig, Ralf J.; Borradori, Luca; Díaz, Luis A.; Hashimoto, Takashi; Hertl, Michael; Ibrahim, Saleh M.; Jonkman, Marcel F.; Kitajima, Yasuo; Murrell, Dédée F.; Schmidt, Enno; Shimizu, Hiroshi; Stanley, John R.; Woodley, David T.; Zillikens, Detlef

doi:10.1038/jid.2014.171

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides BP, other rarer subtypes of pemphigoid include epidermolysis bullosa acquisita (EBA), mucous membrane pemphigoid (MMP), pemphigoid gestationis (PG) and linear immunoglobulin A disease (LAD). Facilitated by Victoria Werth and Dédée Murrell, and joined by members of the IPDG, four consensus meetings have been conducted for EBA from 2012 to 2013 . Disease definitions and the newly proposed EBA Disease Area Index (EBADAI) were reviewed and discussed.…”

Section: Epidermolysis Bullosa Acquisitamentioning

confidence: 99%

“…Facilitated by Victoria Werth and D ed ee Murrell, and joined by members of the IPDG, four consensus meetings have been conducted for EBA from 2012 to 2013. 26 Disease definitions and the newly proposed EBA Disease Area Index (EBADAI) were reviewed and discussed. Challenges regarding ocular involvement scoring by the dermatologist and two scoring systems for ocular involvement were also discussed.…”

Section: Epidermolysis Bullosa Acquisitamentioning

confidence: 99%

See 1 more Smart Citation

Outcome measures for autoimmune blistering diseases

Zhao

Murrell

2015

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Outcome measures are crucial in assessing an autoimmune blistering disease's (AIBD) severity as well as its impact on the patient's quality of life (QOL). The standardization of AIBD outcome measures is pivotal to accurately monitor the patient and to pool results from randomized controlled trials for meta-analysis, and thereby provide knowledge of the optimal AIBD therapies. In the past decade, several AIBD severity outcome measures have been developed and validated. For pemphigus severity, the Pemphigus Disease Area Index (PDAI) developed by the International Pemphigus Definitions Group was shown to be the most superior, followed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) by the German group. For bullous pemphigoid severity, the Bullous Pemphigoid Disease Area Index (BPDAI) was shown to be an accurate and valid measure. To quantify the burden of AIBD and its treatments on QOL, the Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL) were also developed, validated, and are now being validated in multiple languages and cultures.

show abstract

Section: Epidermolysis Bullosa Acquisitamentioning

confidence: 99%

Section: Epidermolysis Bullosa Acquisitamentioning

confidence: 99%